microRNA expression alteration after XXXX treatment in HepG-2 cells.

@entity1 @entity4447 @entity15073 @entity96 @entity5 @entity695 @entity16113 @entity10018
BACKGROUND AND AIM: More and more microRNA (miRNA) are found to be involved in @entity5 genesis and progress. @entity4447 has been an effective chemotherapeutic drug in @entity5 therapy for many years. In this study, we aimed to find the miRNA involved in the mechanisms of @entity4447 treatment in @entity5 therapy. METHODS: We detected the expression profile of miRNA by miRNA microarray and quantitative real-time polymerase chain reaction. Cell viability assay, flow cytometry analysis, prediction of miRNA targets, Western blot analysis and luciferase reporter assay were carried out to determine the role of one selected miRNA, namely @entity695 , in affecting the biological behaviors of HepG-2 cells. RESULTS: Among the 677 @entity1 miRNA in the microarray, five miRNA were upregulated and four were downregulated in HepG-2 cells treated with @entity4447 compared to their controls. If only changes above two folds were considered, four miRNA were identified, namely miR-24, @entity695 , @entity15073 and @entity10018 , which were all upregulated. Among them, @entity695 showed a positive therapeutic effect in @entity96 cells by inhibiting cell growth and inducing cell apoptosis, and @entity16113 was confirmed to be the target gene of @entity695 . Furthermore, a synergy effect was detected between @entity695 and @entity4447 . CONCLUSIONS: @entity4447 altered miRNA expression profile in HepG-2 cells. Among the altered miRNA, @entity695 seemed to take a role in the mechanism of @entity4447 in @entity96 therapy. The synergy effect between @entity695 and @entity4447 may offer this drug a new chance in @entity5 therapy by decreasing its dose and toxic side-effects.
